As previous studies have shown that KLK7 mediates both proteolytic and nonproteolytic functions in ovarian cancer (Dong et al., 2014; Kryza et al., 2016), we used an enzymatically inactive KLK7 mutant, where the active site serine residue has been replaced by alanine. The gene discussed is KLK7; the disease is ovarian cancer.